Aptorum Group Ltd
Business
Aptorum Group Ltd is a clinical-stage biopharmaceutical holding company focused on discovery, development and commercialization of therapeutic assets and diagnostics technologies. It develops novel and repurposed therapeutics targeting oncology and infectious diseases and co-develops PathsDxTest, a molecular NGS-based rapid pathogen identification platform. The company operates through subsidiaries including Aptorum Therapeutics Limited, Acticule Life Sciences Limited and Paths Diagnostics Pte. Limited and manages lead projects ALS-4, SACT-1 and PathsDxTest. Its operations and distribution activities are conducted primarily through its subsidiaries and collaborations across Hong Kong, Canada, the United States, Europe and other international jurisdictions.
Summary from filing dated 2025-04-30
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-1.36M |
| Total assets | $18.69M |
| Total liabilities | $4.90M |
| Stockholders' equity | $23.12M |
| Operating cash flow | $-1.84M |